Pharmaceutical - Pharmaceutical, Dermatologicals

Filter

Popular Filters

1 to 25 of 110 results

Ranbaxy to distribute Cipher’s isotretinoin product in Brazil

25-07-2014

Canada’s Cipher Pharmaceuticals has signed a definitive distribution and supply agreement with India’s…

BrazilCipher PharmaceuticalsDermatologicalsIsotretinoinLicensingPharmaceuticalRanbaxy Laboratories

Sandoz in deal to commercialize Anacor’s Kerydin in USA

Sandoz in deal to commercialize Anacor’s Kerydin in USA

22-07-2014

USA-based Anacor Pharmaceuticals has entered into an exclusive agreement with Sandoz, a subsidiary of…

Anacor PharmaceuticalsBusiness FinanceDermatologicalsKerydinLicensingMajorNovartisOnychomycosisPharmaceuticalPharmaceutical industryPharmaDermSandozTopical solutionUSA

LEO Pharma strikes global dermatology deal with KLOK Tech

LEO Pharma strikes global dermatology deal with KLOK Tech

16-07-2014

Danish dermatology specialist LEO Pharma and Canada’s KLOX Technologies, both privately-held companies,…

Acne vulgarisDermatologicalsGlobalKLOX TechnologiesLEO PharmaLicensingPharmaceutical

Stada Arz acquires Flexitol rights for UK and Ireland

Stada Arz acquires Flexitol rights for UK and Ireland

10-07-2014

Thornton & Ross, the UK subsidiary of German generic and branded drugmaker Stada Arzneimittel, has purchased…

DermatologicalsFlexitolIrelandMergers & AcquisitionsPharmaceuticalSTADA ArzneimittelThornton & RossUK

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

10-07-2014

Data published in the New England Journal of Medicine has shown secukinumab to be more effective at treating…

DermatologicalsetanerceptNovartisPharmaceuticalPsoriasisResearchsecukinumabUSA

FTC puts conditions on Valeant’s acquisition of Precision Dermatology

FTC puts conditions on Valeant’s acquisition of Precision Dermatology

04-07-2014

Canada’s Valeant Pharmaceuticals International and its takeover target Precision Dermatology have agreed…

ActavisDermatologicalsMatawan PharmaceuticalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyRegulationValeant Pharmaceuticals International

UCB and Dermira link up for Cimzia in dermatology

UCB and Dermira link up for Cimzia in dermatology

03-07-2014

Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered…

CanadaCimziaDermatologicalsDermiraEuropeLicensingPharmaceuticalResearchUCBUSA

US FDA grants Valeant approval for Jublia NDA

US FDA grants Valeant approval for Jublia NDA

09-06-2014

Canadian drugmaker Valeant Pharmaceuticals International’s US subsidiary has received approval from…

CanadaDermatologicalsefinaconazoleJubliaPharmaceuticalRegulationUS Food and Drug AdministrationValeant Pharmaceuticals

Positive Ph III results with Cubist’s Sivextro in ABSSSI

Positive Ph III results with Cubist’s Sivextro in ABSSSI

06-06-2014

USA-based Cubist Pharmaceutical saw its share rise 3.1% to $70.80 in morning trading Friday, after the…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDermatologicalsPharmaceuticalResearchSivextro

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

28-05-2014

US health care giant Johnson & Johnson subsidiary Janssen today received a negative opinion from UK watchdog…

DermatologicalsInflammatory diseasesJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelaraUK

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

28-05-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into an agreement to…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceuticalValeant Pharmaceuticals

Pfizer’s tofacitinib meets primary endpoints in Ph III psoriasis study

26-05-2014

US pharma giant Pfizer on Friday announced positive results from the Oral treatment Psoriasis Trial (OPT)…

Anti-Arthritics/RheumaticsDermatologicalsPfizerPharmaceuticalResearchtofacitinib

New psoriasis therapies go head-to-head with existing drugs

06-05-2014

Three promising new drug classes are heating up the market for moderate-to-severe plaque psoriasis therapeutics,…

AlphaCytokinesDermatologicalsGlobalImmunologyMarkets & MarketingModerate-to-severe plaque psoriasisPharmaceuticalPharmacology

Pierre Fabre gains EU approval for Hemangiol, for proliferating infantile hemangioma

Pierre Fabre gains EU approval for Hemangiol, for proliferating infantile hemangioma

06-05-2014

French drugmaker Pierre Fabre Dermatologie Laboratories has obtained European Commission authorization…

DermatologicalsEuropeHemangeolHemangiolPharmaceuticalPierre FabreRegulation

Free drug samples can change prescribing habits of US dermatologists

17-04-2014

The availability of free medication samples in dermatology offices in the USA appears to change prescribing…

DermatologicalsMarkets & MarketingPharmaceuticalUSA

Aqua’s acquisition to push Almirall in US dermatology market

03-04-2014

Spain’s largest drugmaker, Almirall (ALM: MC), announced at the end of last year the acquisition of…

AlmirallAqua PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceutical

FDA advisory unanimously recommends Durata’s Dalvance

FDA advisory unanimously recommends Durata’s Dalvance

01-04-2014

The US Food and Drug Anti-Infective Drugs Advisory Committee voted 12 to 0 that Durata Therapeutics’…

Antibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsNorth AmericaPharmaceuticalRegulationUSA

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

31-03-2014

Hong Kong-listed Lansen Pharmaceutical has acquired the pharmaceutical product, marketed and sold in…

Asia-PacificChinaDermatologicalsLansen PharmaceuticalMergers & AcquisitionsNovartisPharmaceuticalSicorten

Real world data shows that Stelara offers lower rates of psoriasis infection

Real world data shows that Stelara offers lower rates of psoriasis infection

27-03-2014

New interval findings from an international prospective disease-based registry provide a review of important…

DermatologicalsJanssenPharmaceuticalResearchStelara InjectionUSA

Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis

25-03-2014

New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis

24-03-2014

US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…

DermatologicalsEnbrelPfizerPharmaceuticalResearchtofacitinibXeljanz

New survey confirms psoriasis and psoriatic arthritis patients frequently undertreated or not treated at all

21-03-2014

A unique and extensive survey provides the first-of-its-kind multinational look into the impact psoriasis…

Anti-Arthritics/RheumaticsCelgeneDermatologicalsHealthcarePharmaceutical

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

1 to 25 of 110 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top